Previous studies have shown that tumor responsiveness to ICB therapy is regulated by multiple factors, including the abundance of PD-L1 expression, the level of tumor mutation burden (TMB), and the “heat” of tumor immune microenvironment (TIME) [44–46]. The gene discussed is CD274; the disease is neoplasm.